Batilol
CAS 544-62-7
Batilol (CAS 544-62-7) is a Phase 2 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 17483.414137931035 nM | 58 | - |
| - | Potency | 25773.783333333336 nM | 6 | - |
| - | AC50 | 13803.299999999997 nM | 3 | - |
| - | IC50 | 40000 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Batilol used for in pharmaceutical contexts?
Batilol (CAS 544-62-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Batilol?
No adverse-event association or SIDER side-effect rows are rendered for Batilol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Batilol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Batyl Alcohol with EU status "permitted".
What clinical phase is Batilol in?
Batilol is rendered with ChEMBL max phase 2.